US biotech Moderna (Nasdaq: MRNA) on Monday announced that the first participant has been dosed in the Phase I study of its mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
Market reaction was dramatic, with the stock closing up 24.4% at $26.40 yesterday, and leaping a further 21.6% to $32.20 by late morning trading today.
This Phase I study is being conducted by the US National Institutes of Health (NIH) under its own Investigational New Drug (IND) application, with the race now on to develop an immunization against COVID-19.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze